TSUMURA & CO. (4540) Stock Price

Market cap
¥290.1B
P/E ratio
11.8x
Tsumura manufactures prescription and over-the-counter medicines, specializing in herbal extract powders and raw medicinal herbs across Japan, China, Laos, and the US.

Price and Volume

Market Cap

Subscribe to premium to access
Market Cap.

Check pricing

PER

Subscribe to premium to access
PER.

Check pricing

PBR

Business Overview

Tsumura operates diverse business segments centered on pharmaceuticals. In Japan, the company manufactures and sells prescription and over-the-counter medicines through Tsumura Inc., which plays a primary role. Logistics Tsumura Inc. handles transportation and warehousing, while Yubari Tsumura Inc. manages the cultivation, procurement, processing, and storage of raw medicinal herbs.

In China, Tsumura (China) Limited Company serves as the regional headquarters, with Ping An Tsumura Limited Company and Ping An Tsumura Pharmaceutical Limited Company overseeing business operations. Shanghai Tsumura Pharmaceutical Limited Company and Tianjin Tsumura Pharmaceutical Limited Company manufacture and sell herbal extract powders. Shenzhen Tsumura Pharmaceutical Limited Company and Shengshi Baicao Pharmaceutical Limited Company handle the procurement, processing, storage, and sales of raw medicinal herbs.

In Laos, LAO TSUMURA CO.,LTD. manages the cultivation, procurement, processing, and storage of raw medicinal herbs. In the United States, TSUMURA USA, INC. is responsible for pharmaceutical development. Through these operations, Tsumura provides pharmaceutical-related services on a global scale.

Management Policy

Tsumura is pursuing a distinctive growth strategy aimed at integrating traditional Chinese medicine with Western medicine. The "TSUMURA VISION 'Cho-WA' 2031" refreshed in 2022 sets forth the goal of realizing a future where mind and body, individual and society are in harmony. Under this vision, Tsumura has established its purpose—"Living fully, for each person"—and formulated the sustainability vision "Passing on the power to live with nature to the future."

Tsumura's medium-term management plan for fiscal years 2025–2027 addresses five strategic priorities: promoting growth in the Kampo medicine market, creating new value through KAMPOmics, expanding business in the Chinese market, digitally transforming the Kampo value chain, and strengthening human capital. Through these initiatives, Tsumura aims to expand its business in Japan and China while enhancing corporate value.

Tsumura also prioritizes the pursuit of quality and safety, strengthening quality assurance based on "Tsumura Quality Culture." This ensures stable supply of high-quality, trusted products and improves customer satisfaction. Additionally, Tsumura is advancing global expansion, including pharmaceutical development in the United States and expansion of its Chinese medicine business in China.

AI Chat